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MMP-9 (matrix metalloproteinase 9) plays a critical role in
tumour progression. Although the biochemical properties of
the secreted form of proMMP-9 are well characterized, little
is known about the function and activity of cell surface-asso-
ciated proMMP-9. We purified a novel 82 kDa species of
proMMP-9 from the plasma membrane of THP-1 leukaemic
cells, which has substantial differences from the secreted 94 kDa
proMMP-9. The 82 kDa form was not detected in the medium
even upon stimulation with a phorbol ester. It is truncated
by nine amino acid residues at its N-terminus, lacks O-linked
oligosaccharides present in the 94 kDa proMMP-9, but retains
N-linked carbohydrates. Incubation of 94 kDa proMMP-9 with
MMP-3 generated the well-known 82 kDa active form, but the
82 kDa proMMP-9 was converted into an active species of 35 kDa,
which was also produced by autocatalytic processing in the
absence of activating enzymes. The activated 35 kDa MMP-9 effi-
ciently degraded gelatins, native collagen type IV and fibronectin.
The enzyme was less sensitive to TIMP-1 (tissue inhibitor
of metalloproteinase 1) inhibition with IC50 values of 82 nM
compared with 1 nM for the 82 kDa active MMP-9. The synthetic
MMP inhibitor GM6001 blocked the activity of both enzymes,
with similar IC50 values below 1 nM. The 82 kDa proMMP-9 is
also produced in HL-60 and NB4 leukaemic cell lines as well
as ex vivo leukaemic blast cells. It is, however, absent from
neutrophils and mononuclear cells isolated from peripheral blood
of healthy individuals. Thus, the 82 kDa proMMP-9 expressed on
the surface of malignant cells may escape inhibition by natural
TIMP-1, thereby facilitating cellular invasion in vivo.
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INTRODUCTION
MMPs (matrix metalloproteinases) represent a family of struc-
turally and functionally related zinc-dependent endopeptidases
capable of digesting extracellular matrix components [1–4].
In addition to their degradative function, they have abilities
to process regulatory proteins, including cytokines, growth
factors or their receptors [3]. Unbalanced MMP activities are
involved in numerous pathological events, such as tumour growth
and metastasis, arthrosis, arthritis, nephritis, neurodegenerative
disease and fibrosis [2,4]. Production and activity of MMPs in
cells is controlled precisely at the level of gene expression and
is modulated by a variety of stimuli (e.g. cytokines, hormones
or extracellular matrix proteins), by activation of the latent
proenzymes, and by inhibition by endogenous TIMPs (tissue
inhibitors of metalloproteinases) [5].
Two members of the MMP family, gelatinase A (MMP-2) and
gelatinase B (MMP-9), are subclassified for their preferential
abilities to degrade denatured collagens (gelatin) and collagen
type IV, the main component of basement membranes. Moreover,
these enzymes have the potential to process TGF-β (transforming
growth factor β) [6], interleukin 8 [7], and interleukin 1β [8]
into their biologically active forms. In contrast to MMP-2, which
is often expressed in a constitutive manner, MMP-9 synthesis
and secretion are regulated, and in most cell types it occurs only
upon stimulation. Although MMP-9 production can be observed
in diverse cell types, its synthesis in cells of haematopoietic
origin, such as neutrophil granulocytes [9], monocytes [10] and
macrophages [11], appears as major source of MMP-9 in humans.
Leukocytes that infiltrate neoplastic tissue have been shown to
act as co-conspirators of carcinogenesis by providing the tumour
with MMP-9 [12]. Moreover, in acute myeloid leukaemia, both
constitutive and stimulated release of MMP-9 is observed in
various cell lines and ex vivo blast cells [13–17], indicating that
this enzyme is also involved in leukaemic cell dissemination [18].
Direct evidence for a crucial role of MMP-9 in the invasion
and metastatic capacity of tumour cells has been obtained by
transfection and ribozyme-based approaches [19,20], suggesting
MMP-9 as a preferential target in the development of anti-cancer
drugs.
MMP-9 is synthesized as a pre-proenzyme and is secreted
from the cells in a glycosylated proenzyme form [21] with a
molecular mass varying from 91–96 kDa depending on the cell
type [9,10,13,21,22]. ProMMP-9 may form a tight complex with
TIMP-1 [21], which influences both activation and activity of
this enzyme. In vitro activation of latent MMP-9 is achieved
by incubation with organomercurials or several proteinases [23].
Under physiological conditions, a proteolytic cascade involving
MMP-3 or the plasminogen activator/plasmin system is postulated
to convert proMMP-9 into its active form [24,25].
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Cell surface association of MMP-9 has been documented in
various cell types, including epithelial cells [26], endothelial cells
[27], neutrophil granulocytes [28,29], monocytes [30] and tumour
cells [6,24,31–34]. Binding of MMP-9 to the plasma membrane
is mediated by interaction of the enzyme with a distinct array of
surface molecules [35,36], including CD44 [6,31,34], β1-integrins
[27] and the α2 chain of collagen IV [33]. MMP-9 co-localized
with CD44 on the surface of neoplastic cells was demonstrated
to activate latent TGF-β, thereby promoting tumour invasion,
growth and angiogenesis [34]. MMP-9 can also induce tumour-
associated angiogenesis by release of vascular endothelial growth
factor trapped in the extracellular matrix [37]. Thus, MMP-9
seems to be of relevance in carcinogenesis by activating and
liberating tumour promoting factors from the cancer-cell surface
and surrounding extracellular matrix [38]. Nevertheless, it is still
unclear how the enzymatic activity of MMP-9 is controlled at the
pericellular space.
In the present study, we identified a novel non-secreted 82 kDa
proMMP-9 species localized at the surface of leukaemic cells.
This particular zymogen form has not been recognized previously
as an independent enzyme, probably due to its high similarity to
‘regular’ proMMP-9, which after secretion is able to re-associate
to the cell membrane. Comparative analysis on purified enzymes
showed clearly structural and functional differences between the
two proMMP-9 species, suggesting a specific role for the 82 kDa
proMMP-9 in surface-associated proteolysis of leukaemic cells.
EXPERIMENTAL
Cell culture
The cell lines THP-1 (acute monocytic leukaemia), HL-60
(acute myeloblastic leukaemia), NB4 (acute promyelocytic
leukaemia) and HT1080 fibrosarcoma cells were purchased from
the German Collection of Microorganisms and Cell Cultures
(DSMZ, Braunschweig, Germany). Cells were grown in RPMI-
1640 supplemented with 10% (v/v) heat-inactivated fetal calf
serum, 2 mM glutamine, 100 units/ml penicillin and 100 µg/ml
streptomycin. Incubation was performed at 37 ◦C in a humidified
air atmosphere in the presence of 5% CO2. Cells were passaged
twice a week. For all further experiments cells were washed two
times with serum-free medium and maintained under serum-
free conditions in RPMI-1640 supplemented with 1% (v/v)
Nutridoma SP (Roche Applied Science, Mannheim, Germany).
Mononuclear cells and polymorphonuclear cells/neutrophil
granulocytes were isolated from peripheral blood of healthy
volunteers, and leukaemic blast cells from peripheral blood of
three patients with acute myeloid leukaemia by Percoll (Sigma,
Munich, Germany) density gradient centrifugation as described
previously [16]. All samples were collected at the University
Hospital of Munich with consent of the persons involved. Purified
cell fractions were washed twice and resuspended in serum-
free medium for subsequent experiments. Cell viability was
determined using the Trypan Blue exclusion test.
Phorbol ester stimulation and preparation of crude cell extracts
For stimulation experiments, cells were cultured at a density of 1 ×
106 cells/ml either in serum-free medium alone or in medium
containing 50 ng/ml PMA for 24 h. Thereafter, non-adherent cells
were separated from culture supernatants by centrifugation at
400 g for 15 min at 4 ◦C. Adherent cells were scraped to remove
them from the culture dish. The conditioned media were stored at
−20 ◦C. Cell pellets were washed three-times in cold TBS (Tris-
buffered saline; 50 mM Tris/HCl, pH 7.4, and 150 mM NaCl). For
lysis and protein extraction, cells were resuspended at a density of
1 × 107 cells/ml in lysis buffer [TBS containing 1% (v/v) Triton
X-100]. To prevent (auto-)proteolytic degradation, 10 mM EDTA
and a mixture of inhibitors of metallo-, serine- and cysteine-
proteinases (Complete-Mini, Roche Applied Science) was added
to the lysis buffer. The cell suspension was vortexed and incubated
for 30 min at 4 ◦C. Subsequently, the supernatants were collected
by centrifugation at 16000 g for 15 min at 4 ◦C and stored at
−20 ◦C. For zymography or immunoblot analysis, gelatinases
present in the cell extracts were enriched by gelatin–Sepharose
chromatography as described below.
Zymographic analysis and quantification of gelatinases
in zymograms
Zymography was performed in precast 10% polyacrylamide
minigels containing 0.1% gelatin as substrate (Invitrogen,
Groningen, The Netherlands). Samples were run under non-
reducing conditions without prior boiling. Conditioned medium
from PMA-treated HT1080 fibrosarcoma cells containing
proMMP-9 (94 kDa), proMMP-2 (72 kDa) and activated MMP-2
(66 kDa) [22] was used as marker for electrophoretic mobility
of gelatinases in zymograms. After electrophoresis, gels were
washed twice for 15 min in 2.7% (v/v) Triton X-100 (diluted
in water) on a rotary shaker to remove SDS and to allow
proteins to renature. The gels were then incubated in a buffer
containing 50 mM Tris/HCl (pH 7.5), 200 mM NaCl, 5 mM
CaCl2 and 0.2% Brij35 (Invitrogen) for 18 h at 37 ◦C. The
zymograms were stained for 90 min with 0.02% Coomassie
Blue R-350 in a 30% (v/v) methanol/10% (v/v) acetic acid
solution by the use of PhastGel-Blue-R tablets (GE Healthcare
Life Sciences, Freiburg, Germany). Quantification of gelatinolytic
activity in zymograms was performed as described previously
[39]. Zymograms were scanned using an Umax ImageScanner
driven by the MagicScan software and analysed using the
ImageMaster-1D Elite quantification software (GE Healthcare
Life Sciences). The linear range of the assay was determined
by the use of recombinant MMP-9 (Calbiochem, Schwalbach,
Germany) as calibration standard.
SDS/PAGE and immunoblot analysis
SDS/PAGE was performed under reducing conditions in
precast 4–12% (w/v) polyacrylamide minigels (Invitrogen).
For electrophoresis and blotting the NuPAGE Bis/Tris system
(Invitrogen) was used according to the manufacturer’s
instructions. After electrophoretic separation, proteins were
either stained with silver according to a method described by
Heukeshoven and Dernick [40] or were electroblotted on to PVDF
membranes (Millipore, Bedford, MA, U.S.A.). The membranes
were blocked in 10% (w/v) non-fat milk in TBS for 1 h at room
temperature (21 ◦C). Thereafter, the blots were incubated with
0.5 µg/ml primary rabbit polyclonal antibody against proMMP-
9 (M-5177; Sigma) for 1 h at room temperature, which allows
detection of both latent and activated enzyme forms. A mouse
monoclonal antibody (IM09L, clone 6-6B; Calbiochem) that only
recognizes the latent proMMP-9 and not the activated species
under reducing conditions for immunoblotting was used at a
concentration of 0.5 µg/ml. After washing, blots were incubated
for 15 min with horseradish-peroxidase-conjugated anti-rabbit
IgG (GE Healthcare Life Sciences) as secondary antibody at a
dilution of 1:1000. The blots were then developed applying the
ECL (enhanced chemiluminescence) system as recommended by
the manufacturer (GE Healthcare Life Sciences). For molecular
mass determination of proteins detected on the blots, recombinant
protein standards (Invitrogen and Bio-Rad, Munich, Germany)
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were used. The developed films were scanned and analysed using
the ImageMaster-1D Elite software.
Confocal laser scanning microscopy
THP-1 cells were grown on 8-well CultureSlides (BD Falcon,
Heidelberg, Germany) for 24 h under serum-free conditions in
the presence of 50 ng/ml PMA. The cells were washed, and
then fixed in 3.7% (v/v) formaldehyde in PBS for 15 min at
room temperature. The fixed cells were blocked with 2% (w/v)
BSA in PBS for 15 min, and then incubated with 50 µg/ml of
monoclonal anti-MMP-9 antibody (GE-213, NeoMarkers, Union
City, CA, U.S.A.) or with 50 µg/ml of mouse IgG1 isotype
control antibody (DAKO, Hamburg, Germany) for 1 h at 37 ◦C.
The secondary fluorescence-conjugated antibody used was Alexa
Fluor® 488 anti-mouse IgG (Molecular Probes, Eugene, OR,
U.S.A.). Detection was carried out at an excitation wavelength
of 488 nm, beam splitter HFT 488, and emission at 505–530 nm
on a Zeiss LSM 510 confocal scanning microscope equipped with
a Plan-Neofluar 100×/1.3 oil immersion objective. Each image
represents a single section with a field depth of 1 µm.
Subcellular fractionation and isolation of plasma membranes
THP-1 cells (1 × 106/ml) were cultured for 24 h under serum-
free conditions in the presence of 50 ng/ml PMA. Cells were
harvested and washed three times with ice-cold PBS. All of
the following procedures were carried out at 4 ◦C according to
a method described previously [26] with minor modifications.
Cells were resuspended at 2 × 107/ml in buffer containing 25 mM
Tris/HCl (pH 7.5), 8.5% (w/v) sucrose, 50 mM NaCl and
proteinase inhibitors (Complete-Mini, Roche Applied Science)
at concentrations recommended by the manufacturer. The cell
suspension was homogenized using a Dounce homogenizer and
centrifuged for 10 min at 3000 g. The pellet (nuclear fraction)
was discarded and the supernatant (postnuclear fraction) was
centrifuged at 25000 rev./min for 3 h in a Kontron ultracentrifuge
with a TFT 28/38 rotor (Kendro, Hanau, Germany). The
supernatant (cytosolic fraction) was collected and stored at
−20 ◦C. The pellet (crude membrane fraction) was resuspended
in buffer containing 25 mM Tris/HCl (pH 7.5), 50 mM NaCl
and proteinase inhibitors (Complete-Mini). The sample was
layered on to a discontinuous density gradient of 20, 30, 50
and 60% sucrose in water and once more centrifuged at
25000 rev./min for 3 h. The 30–50% interphase was carefully
aspirated, resuspended in buffer containing 25 mM Tris/HCl
(pH 7.5), 50 mM NaCl and 5 mM EDTA and centrifuged at
25000 rev./min for a further 3 h. The pellet (enriched plasma
membrane fraction) was resuspended in the same buffer and stored
at −70 ◦C. The successful enrichment of plasma membranes
was verified by immunoblot detection of PMCA-ATPase
(plasma membrane-localized calcium-dependent ATPase) using
monoclonal antibodies against this enzyme (Affinity Bioreagents,
Golden, CO, U.S.A.).
Cell surface protein biotinylation and immunoprecipitation
Labelling and detection of proteins localized on the surface
of THP-1 cells was performed by using the ECL protein
biotinylation module (GE Healthcare Life Sciences) according
to the manufacturer’s instructions. Cells (2 × 106/ml) were grown
under serum-free conditions in the presence of 50 ng/ml PMA for
24 h. Cells were harvested by centrifugation at 600 g at 4 ◦C,
and then washed twice with ice-cold PBS. The cell viability
was 95%, as determined by Trypan Blue staining. Cells
were then diluted to 1 × 107/ml in PBS and incubated with
40 µl/ml of the water-soluble and cell impermeable biotinylation
reagent (biotinamidocaproate N-hydroxysuccinamide ester) for
15 min at 4 ◦C on a roller mixer. Control cells received
vehicle only. After incubation, cells were washed twice in
PBS and extracted with Triton X-100 as described above.
For gelatinase enrichment, cell extracts were passed through a
gelatin–Sepharose affinity column (see below). Elution fractions
containing gelatinolytic activity were pooled, dialysed against
50 mM Tris/HCl (pH 7.5), 0.3% Triton X-100 and 5 mM EDTA,
and concentrated using Microcon YM10 devices (Millipore).
For immunoprecipitation, enriched gelatinase samples were then
incubated with 9 µg/ml of monoclonal anti-MMP-9 antibody
(GE-213, NeoMarkers) and Protein G–Sepharose beads overnight
at 4 ◦C under constant shaking. The Protein G–Sepharose
beads were washed three times with ice-cold PBS, resuspended
in reducing electrophoresis sample buffer (141 mM Tris/HCl,
pH 8.5, 1 M glycerol, 73 mM lithium dodecyl sulfate, 0.5 mM
EDTA and 20 mg/ml dithiothreitol), boiled, and centrifuged
at 16000 g for 1 min at 4 ◦C. The supernatant containing
immunoprecipitated antigens was separated by SDS/PAGE (4–
12% gels) under reducing conditions, and blotted as described
above. After blocking and washing of the membrane, detection
of biotinylated proteins was achieved by incubation with
streptavidin-conjugated horseradish peroxidase (diluted 1:1500)
and detection with ECL. The specificity of detection was
controlled by processing non-biotinylated cells in the same way
as described for biotinylated cells.
Gelatin–Sepharose affinity chromatography and gel filtration
Purification of MMP-9 was performed as described previously by
us [41] with some modifications. All procedures were carried out
at 4 ◦C with buffers containing proteinase inhibitors (Complete-
Mini) and 5 mM EDTA to avoid autoproteolytic processing.
THP-1 cell-associated MMP-9 forms were purified from crude
cell extracts (0.1–0.5 ml) or postnuclear fractions (40 ml) by
Triton X-100 extraction with vigorous vortexing and incubation
on ice for 30 min. After centrifugation at 3000 g for 15 min,
the supernatant was applied to a gelatin–Sepharose column
of 2 ml bed vol. equilibrated with 50 mM Tris/HCl (pH 7.5),
400 mM NaCl, 5 mM EDTA and 0.1% Brij 35 at a flow rate
of 0.03 ml/min using the FPLC system (GE Healthcare Life
Sciences). After the column had been washed in the same buffer,
gelatin-binding proteins were eluted by 5% (v/v) DMSO in
column buffer. Gelatinase containing fractions were assessed
by zymography, pooled and concentrated by approx. 10-fold
(Centricon YM10, Millipore). For separation of 82 kDa and
94 kDa MMP-9 forms, the sample (0.5 ml) was then applied to
a Superdex G-200 gel filtration column (1.6 cm × 60 cm; GE
Healthcare Life Sciences) equilibrated with 50 mM Tris/HCl
(pH 7.5), 150 mM NaCl, 5 mM EDTA and 0.02% Brij 35
at a constant flow of 0.4 ml/min. Fractions (1 ml) containing
94 kDa MMP-9 or 82 kDa MMP-9 respectively, were pooled and
concentrated. Protein concentrations were determined using the
Coomassie Plus Protein Assay Reagent (Pierce, Rockford, IL,
U.S.A.). The enzyme preparations were stored at −20 ◦C.
The secreted 94-kDa species of proMMP-9 was purified from
culture supernatants of PMA-treated THP-1 cells. Conditioned
medium (1 litre) was adjusted to 5 mM EDTA and 0.02%
Brij 35, and concentrated to a final volume of 50 ml using
an Amicon Diaflo apparatus fitted with a YM-10 membrane
(Amicon, Beverly, MA, U.S.A.). Thereafter, the material was
processed by gelatin–Sepharose affinity chromatography and
gel filtration as described above. Selective denaturation of co-
purifying TIMP molecules was performed according to a method
published previously [42].
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Microsequencing and MALDI–TOF-MS (matrix-assisted
laser-desorption ionization–time-of-flight MS)
Samples of purified gelatinases were separated by SDS/PAGE
(10% gel) and electroblotted on to glass fibre membranes
(Glassybond, Biometra, Go¨ttingen, Germany) [43]. Coomassie
Blue stained bands were cut out and sequenced in a 492cLC gas
phase sequencer (Applied Biosystems, Foster City, CA, U.S.A.).
For MS analysis, samples were separated by SDS/PAGE and the
protein bands were excised and digested directly in the gel with
trypsin as outlined by Eckerskorn and Lottspeich [44]. Peptide
mass fingerprinting was performed according to Meister et al.
[45] using a Bruker reflex III MALDI–TOF mass spectrometer
equipped with a 337 nm nitrogen laser (Bruker-Franzen, Bremen,
Germany).
Deglycosylation of purified proMMP-9 forms
Purified proMMP-9 preparations were digested by enzymes
provided by the Glycoprotein Deglycosylation Kit from Calbio-
chem (San Diego, CA, U.S.A.) following the denaturing or non-
denaturing standard protocols of the manufacturer. For Western
blot detection of deglycosylated proteins, samples (30 µl) were
mixed with reaction buffer (250 mM PBS, pH 7.0) and denatur-
ation solution [2% (w/v) SDS and 1 M 2-mercaptoethanol] and
heated at 100 ◦C for 5 min. After cooling to room temperature,
Triton X-100 solution [15% (v/v) Triton X-100 diluted in
water] was added at a final concentration of 1% to remove
free SDS. Subsequently, samples were incubated with different
glycosidases alone or in combination in a final reaction volume
of 47.5 µl for 3 h at 37 ◦C. N-glycosidase F (2.5 units) was
added to remove asparagine-linked (N-linked) oligosaccharides.
Cleavage of serine/threonine-linked (O-linked) sugar residues
was achieved by simultaneous incubation with a combination of
endo-α-N-acetylgalactosaminidase (0.6 milliunits), α2-3,6,8,9-
neuraminidase (1.25 milliunits), β-1,4-galactosidase (0.75 milli-
units) and β-N-acetylglucosaminidase (2 milliunits) according to
the manufacturers instructions. Mobility shift analysis of digested
samples was performed by SDS/PAGE and immunoblotting
using anti-MMP-9 antibodies as described above. To preserve
enzymatic activity of gelatinases during the deglycosylation
reaction, samples were incubated with glycosidase for 4 days at
37 ◦C under non-reducing conditions and subsequently analysed
by zymography.
Activation of purified proMMP-9 forms and reaction
with α2-macroglobulin
Purified 82 kDa proMMP-9 from THP-1 cell extracts and 94 kDa
proMMP-9 from culture supernatants were diluted to a final
concentration of 50 ng/ml in enzyme buffer containing 50 mM
Tris/HCl (pH 7.5), 150 mM NaCl, 5 mM CaCl2, 1 µM ZnCl2
and 0.02% Brij 35, and were treated with or without equimolar
amounts of active recombinant MMP-3 prepared according to
the method of Suzuki et al. [46] at 37 ◦C in a total volume of
250 µl. Aliquots were taken at different time intervals and stored
on ice prior to analysis for gelatinolytic activity in zymograms. For
identification of catalytically active gelatinase species, samples
pre-treated with or without MMP-3 for 30 min at 37 ◦C were
reacted with an excess (500 µg/ml) of α2-macroglubulin (Roche
Applied Science) for 30 min at 37 ◦C and subsequently applied to
zymographic analysis.
Cleavage of biological substrates
Purified 82 kDa proMMP-9 was autocatalytically activated by
incubation in buffer containing 50 mM Tris/HCl (pH 7.5),
150 mM NaCl, 5 mM CaCl2, 1 µM ZnCl2 and 0.02% Brij 35
for 3 h at 37 ◦C. Activation of the secreted 94 kDa proMMP-9
species was performed by exposure to 1 mM APMA (4-amino-
phenylmercuric acetate) for 2 h at 37 ◦C as described previously
[41]. Successful conversion into their active forms was controlled
by zymography. Native or denatured (by heating to 100 ◦C for
3 min) collagen type IV (400 µg/ml) from Engelbreth–Holm–
Swarm mouse sarcoma cells, 300 µg/ml denatured collagen
type I (rat tail) and 100 µg/ml fibronectin (all from Sigma) were
incubated with or without equimolar amounts (1.5 µM) of
activated enzymes for 48 h at 32 ◦C. The reaction mixtures were
then analysed for degradation products by SDS/PAGE followed
by silver staining of the proteins.
MMP-9 inhibition studies
The active forms of 82 and 94 kDa proMMP-9 were assayed using
a fluorescence-labelled gelatin substrate (Molecular Probes). For
activation 20 nM of purified enzymes were incubated with 1–
5 nM of active recombinant MMP-3 for 1–3 h at 37 ◦C in a buffer
containing 50 mM Tris/HCl (pH 7.5), 150 mM NaCl, 30 mM
CaCl2, 10 µM ZnCl2, and 0.02% Brij 35 (100 µl total volume).
Complete conversion into active MMP-9 forms was controlled by
zymography. For inhibition studies 1 nM of each activated enzyme
was pre-incubated for 30 min at 37 ◦C with or without 0.1–100 nM
of purified TIMP-1 (prepared as described previously [47]), 0.1–
100 nM GM6001 (a broad-spectrum hydroxamic acid inhibitor
of MMPs) (Calbiochem) or 1 mM 1,10-phenanthroline (Sigma)
before the fluorescence-labelled substrate (1.5 µg/ml) was added
to a final volume of 200 µl. After 1 h incubation at 37 ◦C,
substrate hydrolysis was measured using a Molecular Dynamics
Biolumin 960 (GE Healthcare Life Sciences) fluorescence
spectrophotometer with excitation and emission wavelengths set
at 485 and 520 nm respectively.
RESULTS
Detection of secreted and cell-associated forms of MMP-9
THP-1 cells were cultivated in the absence and presence of
PMA. The culture supernatants and cell lysates were analysed
for gelatinase activity by zymography and Western blotting. The
conditioned medium contained 94 kDa proMMP-9, expression of
which was enhanced considerably upon PMA stimulation (Fig-
ure 1). An additional band migrating at the top of the zymogram
gels represented the homodimer of proMMP-9 as observed
under non-reducing conditions of electrophoresis [48]. The
production of 72-kDa proMMP-2 was negligible in these cells
(Figure 1A).
Zymographic analysis of cell lysates from untreated cells
revealed the presence of gelatinolytic activity at 92–94 kDa
consisting of two single merging bands that were significantly
augmented upon PMA treatment, which formed a major zone
of lysis between approx. 88 and 94 kDa (Figure 1A). Under
reducing conditions, Western blot analysis using anti-MMP-9
antibodies detected two distinct bands in cell lysates: a minor
protein with a molecular mass of 94 kDa, which presumably
represents intracellular proMMP-9 prior to secretion, and a major
82 kDa form. Both MMP-9 species were augmented by PMA
treatment (Figure 1B). To assess whether the 82-kDa MMP-9
was generated from 94-kDa proMMP-9 by the Triton X-100
extraction procedure, conditioned medium comprising only the
94-kDa enzyme was treated with extraction buffer for 18 h at
37 ◦C, but no effect on 94 kDa proMMP-9 was observed (results
not shown), demonstrating that the 82 kDa form was not created
by the extraction technique.
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Figure 1 Detection of secreted and cell-associated MMP-9
THP-1 leukaemic cells (1 × 106 cells/ml) were incubated under serum-free conditions for 24 h
in the presence (+) or absence (−) of 50 ng/ml PMA. (A) Aliquots (3 µl) of THP-1 conditioned
medium (CM) and 10 µl aliquots of cell extract (EX) were analysed by zymography. (B) For
immunoblot detection, 15 µl aliquots of gelatinases isolated from conditioned medium and
30 µl aliquots of gelatinases from cell extracts containing 5–10 ng of protein were separated by
SDS/PAGE under reducing conditions, blotted and probed with polyclonal antibodies directed
against MMP-9. Molecular mass standards (M) were used as a reference, and their sizes are
given in kDa to the left-hand and right-hand sides of (A) and (B) respectively.
Cell surface localization of MMP-9
Confocal fluorescence microscopy analysis of THP-1 cells
stimulated with PMA indicated a zonular array of fluorescence
on the plasma membrane, which was weaker in untreated cells
(Figure 2A). With isotype matched primary control antibodies,
instead of anti-MMP-9 antibodies, no fluorescence signals were
obtained.
To analyse in more detail which MMP-9 forms were associated
with the cell surface, plasma membranes were separated from
cytosolic components of PMA-stimulated cells by sucrose density
gradient centrifugation. As determined by immunoblotting, both
plasma membrane and cytosolic fractions contained the two
MMP-9 species each with larger amounts of the 82 kDa form
compared with the 94 kDa form (Figure 2B). PMCA-ATPase,
an integral protein of cellular plasma membranes, was detected
in the membrane fraction, but not in the cytosolic fraction,
demonstrating successful separation and purification of plasma
membranes (Figure 2C).
To verify that MMP-9 was bound to the outer periphery of
the plasma membrane, cell surface proteins of THP-1 cells were
labelled with biotin. Proteins were then extracted from the cells
and MMP-9 was enriched from the extracts by gelatin–Sepharose
chromatography and subsequently immunoprecipitated using
antibodies against MMP-9. The precipitates were then subjected
to SDS/PAGE and blotted. Using the streptavidin–POD
(peroxidase) detection system a strong band at 82 kDa together
Figure 2 Plasma membrane localization of MMP-9
THP-1 cells were cultured in serum-free medium for 24 h in the absence and presence of 50 ng/ml PMA. (A) Cells grown on culture-slides were fixed without permeabilization, then incubated with
monoclonal anti-MMP-9 antibody and stained with Alexa Flour® 488-conjugated anti-mouse IgG. Confocal laser scanning microscopy images taken under fluorescence conditions are shown for
cells incubated with (+PMA) or without PMA (-PMA). (B) PMA-treated cells were homogenized and fractionated by sequential sucrose density ultracentrifugation. Cytosolic (CY) fractions and the
enriched plasma membrane (PM) were examined for the presence of MMP-9 by immunoblot analysis using polyclonal antibodies. Recombinant marker proteins (M) were used as a reference and
the sizes are given in kDa to the right-hand side of the Figure. (C) Immunoblot detection of PMCA-ATPase was performed to verify the successful enrichment of plasma membranes from the cells.
(D) PMA-treated cells were incubated with cell surface protein biotinylation reagent (+) or vehicle alone (−) for 15 min at 4◦C. Proteins were extracted from the cells and MMP-9 was enriched by
gelatin–Sepharose affinity chromatography, and then immunoprecipitated using monoclonal antibodies against MMP-9, subjected to SDS/PAGE and blotted on to PVDF membranes. For detection
of biotinylated proteins, blots were developed with streptavidin-POD. Recombinant marker proteins (M) were used for molecular mass determination, and the sizes are given in kDa to the right-hand
side of the Figure.
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Figure 3 Purification of cell-associated and secreted MMP-9
Cell extracts and conditioned medium from PMA stimulated THP-1 cells were subjected
to gelatin–Sepharose affinity chromatography, followed by gel filtration chromatography.
(A) Zymogram showing a representative analysis of fractions obtained by gel filtration separation
of gelatin–Sepharose enriched material from cell extracts (G-Seph Pool). Fractions 9–13 con-
taining the 94 kDa gelatinase (94k) and fractions 17–21 containing the 82 kDa gelatinase (82k)
were pooled and concentrated. (B) and (C) Purified 82-kDa MMP-9 from cell extracts (82k) and
94-kDa MMP-9 from conditioned medium (94k) were analysed by zymography (200 pg per lane)
(B) and SDS/PAGE with subsequent silver staining (120 ng per lane) (C). HT1080 conditioned
medium containing MMP-9 (94 kDa), MMP-2 (72 kDa) and activated MMP-2 (66 kDa) was
used as a reference (M) in zymograms. Recombinant marker proteins (M) were applied for
molecular mass determination in SDS/PAGE. Sizes are given in kDa to the left-hand side of (A)
and the right-hand side of (B) and (C).
with a faint band of 94 kDa and additional weak protein
bands of low molecular masses were identified (Figure 2D).
These results confirmed that the major MMP-9 detected on the
surface of THP-1 cells was the 82 kDa form.
Purification of cell-associated and secreted forms of MMP-9
To study the biochemical properties of the cell-associated 82-kDa
variant in comparison with the secreted species of MMP-9, both
enzyme forms were purified from cell extracts and culture medium
of THP-1 cells treated with PMA. Gelatinases were first enriched
from crude cell extracts or the conditioned medium by gelatin–
Sepharose affinity chromatography and were further purified by
gel filtration chromatography, which separated the 82 kDa species
from the 94 kDa form (Figure 3A). Analysis of the pooled and
concentrated fractions showed that the purified 82 kDa form
migrated with an apparent mass of approx. 90 kDa in zymograms
(Figure 3B). This may be due to the absence of reducing agents in
zymography, since under reducing conditions of SDS/PAGE with
subsequent silver staining of proteins it showed a single band
with a molecular mass of 82 kDa (Figure 3C).
Microsequencing and MALDI–TOF-MS analysis of purified
MMP-9 forms
As deduced from the molecular mass, we speculated that the
cell-associated 82-kDa species could represent the activated form
of mature MMP-9 lacking the N-terminal proenzyme domain.
To address this question, the MMP-9 forms purified from cell
extracts and conditioned media of PMA-stimulated THP-1
cells were analysed by microsequencing and MS. Assessment
of the N-terminal sequence of the cell-associated 82 kDa variant
revealed a nine amino acid truncation for this enzyme compared
with the regular proMMP-9 (Table 1). In contrast, secreted
94 kDa proMMP-9 contained the complete N-terminus of the
zymogen form (Table 1). Microsequencing of intracellular
94 kDa proMMP-9 failed, which was possibly due to N-terminal
blockage. Further analysis by MALDI–TOF-MS confirmed each
N-terminal sequence (Table 1). The tryptic peptides of both
the secreted and the cell-associated 94 kDa form of MMP-9
showed the N-terminal peptide mass of 1345.7 Da, which agreed
with the predicted mass of that of the full-length proMMP-9.
Mass mapping of the 82 kDa variant revealed a smaller fragment
of 916.5 Da, which matched the calculated molecular mass
lacking the nine N-terminal amino acids of proMMP-9 (Table 1).
These results were in agreement with our findings obtained by
microsequence analysis.
Studies on proMMP-9 glycosylation
Since proMMP-9 is known to be highly glycosylated [21], we
hypothesized that alterations in the pattern of glycosylation might
Table 1 Sequencing and MALDI–TOF-MS analysis of purified MMP-9 forms
THP-1 cells (4.6 × 109) were stimulated with 50 ng/ml of PMA for 24 h. Cell-associated 82- and 94-kDa gelatinases were isolated from cell extracts (EX) and secreted 94 kDa gelatinase from
conditioned medium (CM) by gelatin–Sepharose affinity chromatography. The samples were then subjected to SDS/PAGE under reducing conditions. For N-terminal microsequence analysis, proteins
were blotted and processed using a gas-phase sequencer. The N-terminal amino acid sequences obtained were compared with that of proMMP-9 [21]. For MS analysis, proteins were excised from
the SDS-gel, digested with trypsin and analysed using a MALDI–TOF mass spectrometer. The molecular masses and the corresponding amino acid sequences of the N-terminal peptide fragment
generated by trypsin digestion of purified MMP-9 forms are shown, and compared with that of proMMP-9 [21]. n.d., not detected.
N-terminal peptide fragment after trypsin digestion
Molecular mass (Da)
Gelatinase N-terminal amino acid sequence Determined Calculated Amino acid sequence
1 10 20 6 17
ProMMP-9 A P R Q R Q S T L V L F P G D L R T N L - 1345.7 Q S T L V L F P G D L R
82 kDa (EX) V L F P G D - 916.5 916.5 V L F P G D L R
94 kDa (EX) n.d. 1345.7 1345.7 Q S T L V L F P G D L R
94 kDa (CM) A P R Q R Q S T L V L - 1345.7 1345.7 Q S T L V L F P G D L R
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Figure 4 Glycosylation studies
Aliquots of the purified secreted 94 kDa proMMP-9 (0.25 µg/ml) and the cell-associated
82 kDa proMMP-9 (1 µg/ml) were reduced, denatured and then incubated for 3 h at 37◦C
with either N-glycosidase F (N-GLYC) to remove N-linked oligosaccharides, with glycosidases
(O-GLYC) that digest O-linked carbohydrates or with a combination of these enzymes. Shifts
in electrophoretical mobility were monitored by SDS/PAGE (4–12 % gels) under reducing
conditions and subsequent immunoblotting using polyclonal antibodies against MMP-9. Results
from a representative experiment of three independent determinations are shown. Recombinant
marker proteins (M) were used for molecular mass assessment and the sizes are shown in kDa
to the left-hand side of the Figure.
also account for the difference in molecular mass for the 82 and
94 kDa species. Therefore the purified 82 and 94 kDa proMMP-
9 forms were subjected to digestion with N-glycosidase F.
Western blot analysis demonstrated that both forms of proMMP-
9 were reduced in size by 6 kDa (Figure 4), indicating a similar
extent of N-linked glycosylation for the two proenzymes. When
the proMMP-9 forms were incubated with glycosidases which
remove O-linked carbohydrates, the molecular mass of secreted
94 kDa proMMP-9 was decreased by 9 kDa, whereas that of
the 82 kDa variant remained unchanged (Figure 4). Removal
of all sugar residues from the 82 and 94 kDa proMMP-9 using
both N-linked and O-linked specific glycosidases yielded 76 and
80 kDa proteins respectively (Figure 4). The molecular mass of the
76 kDa protein is in accordance to that calculated from the amino
acid sequence of proMMP-9 [21], confirming that the 82 kDa
proMMP-9 retains N-linked carbohydrates, but lacks O-linked
sugars, whereas the 94 kDa proMMP-9 contains both types of
glycan molecules.
Proteolytic activation of the 82 kDa proMMP-9
To investigate whether N-terminal truncation and lack of O-
glycosylation influence activation of the 82-kDa proMMP-9, the
purified zymogen was incubated with stromelysin 1 (MMP-3),
a potent physiological activator of proMMP-9, and the mode of
activation was compared with that of the 94 kDa proMMP-9.
As determined by zymography and Western blot analysis,
treatment of the 94 kDa proMMP-9 with MMP-3 resulted in
complete conversion into a single 82 kDa MMP-9 within 1 h,
with an intermediate form of approx. 86 kDa (Figure 5A), as
described by Ogata et al. [49]. In contrast, incubation of the 82 kDa
proMMP-9 with MMP-3 initiated rapid conversion into a major
gelatinase with an apparent molecular mass of approx. 35 kDa,
which migrated as a single protein of 35 kDa when analysed by
Western blotting under reducing conditions (Figure 5B). Owing
to the high sensitivity of zymography additional bands with
lower intensity ranging between approx. 25 and 40 kDa were
also detected, which may represent minor activation products
(Figure 5B). Similar to the purified enzyme, 82 kDa proMMP-9
present in plasma membrane fractions from THP-1 cells treated
with MMP-3 led to the formation of 35 kDa gelatinase that was
stable for at least 6 h (Figure 5C). These findings indicate that the
82 kDa proMMP-9, located in the plasma membrane, is different
from the regular secreted 94 kDa proMMP-9 in its susceptibility
to MMP-3 activation.
To examine the activity status of the different MMP-9 species,
we utilized the property of the inhibitor α2-macroglobulin that
binds only to active endopeptidases [50]. The 94 kDa proMMP-9
pre-incubated with α2-macroglobulin and subsequently subjected
to zymography showed no significant decrease in gelatinolytic
activity, whereas for the activated 82 kDa species bound to α2-
macroglobulin the majority of the activity had shifted to the top
of the gel (Figure 5D). The 82 kDa proMMP-9 did not react with
α2-macroglobulin (Figure 5D), suggesting that it is proteolytically
inactive, like the 94 kDa proMMP-9. The activated 35 kDa species
bound to α2-macroglobulin (Figure 5D), indicating that it is an
active enzyme.
Autocatalytic activation of 82 kDa proMMP-9
Incubation of the purified 82 kDa proMMP-9 in enzyme buffer
in the absence of activating agents for 1–6 h at 37 ◦C gradually
converted the enzyme into a major 35 kDa and a minor 25 kDa
gelatinase as determined by zymography (Figure 6A) and
Western blot analysis (Figure 6B). The conversion was almost
complete after 6 h of incubation (Figure 6A). In contrast, the
94 kDa proMMP-9 remained stable and showed no change in
molecular mass under these conditions (Figure 6A). Autocatalytic
processing of the 82 kDa proMMP-9 was not affected by the
addition of TIMP-1 even when the inhibitor was present in a 3-
fold molar excess (Figure 6A). These findings indicate that the
82 kDa proMMP-9 is readily auto-activated compared with
the inert secreted 94 kDa proMMP-9.
Substrate specificities
Like the 94 kDa proMMP-9, the 82 kDa proMMP-9, when
activated, digested denatured collagen type IV and type I
(gelatins), native collagen type IV and fibronectin (Figure 7).
The two enzymes, however, showed different extent in degrading
these substrates. Although activated 94 kDa proMMP-9 prefers
to cleave native type IV collagen to the denatured gelatins, the
activated 82 kDa proMMP-9 digested denatured type I and type IV
collagens more readily than the 94 kDa form (Figure 7).
Inhibition of the 82 kDa and 94 kDa proMMP-9
To examine their susceptibility to inhibition, the activated 82 kDa
and 94 kDa proenzymes were incubated with increasing concen-
trations of TIMP-1, as well as a synthetic MMP inhibitor, and
inhibition of their gelatinolytic activity was monitored. TIMP-1
efficiently blocked the activated 94 kDa proMMP-9 with an IC50
of 1 nM (Figure 8A). In contrast, inhibition of the activated 82 kDa
proMMP-9 by TIMP-1 was significantly weaker with an IC50
value of 82 nM (Figure 8A). Comparable results were obtained
by TIMP-2 (results not shown). The synthetic MMP inhibitor,
GM6001, blocked both forms of MMP-9 with a similar efficiency,
indicated by the IC50 value of 0.5 nM for the activated 94 kDa
form and of 0.8 nM for the activated 82 kDa proMMP-9 (Fig-
ure 8B).
Expression of the 82 kDa proMMP-9 in other leukaemic cells
The molecular mass of the 82 kDa proMMP-9 is identical to that
of the activated form (82 kDa) of 94 kDa proMMP-9. To
distinguish these two enzyme species, we used Western blot
analysis with antibodies that specifically recognize the propeptide,
but not the activated form of MMP-9. As expected, both the
82 kDa proMMP-9 and the 94 kDa proMMP-9, but not their
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Figure 5 Proteolytic activation of proMMP-9 forms and binding to α2-macroglobulin
Purified 94 kDa proMMP-9 from culture supernatants (A) and 82 kDa proMMP-9 from cell extracts (B) were diluted to a final concentration of 50 ng/ml in enzyme buffer. The samples were then
incubated at 37◦C in the presence or absence of equimolar amounts of active MMP-3. Aliquots were taken at different time intervals and analysed by zymography and immunoblotting using
anti-MMP-9 polyclonal antibodies. (C) Enriched THP-1 plasma membranes containing the 94 kDa proMMP-9 (pro-94k) and the 82 kDa proMMP-9 (pro-82k) were incubated with MMP-3. Aliquots
were taken at different time intervals and analysed by zymography. (D) For examination of proteolytic activity the purified 94 kDa proMMP-9 and the 82 kDa proMMP-9 were treated with or without
MMP-3 for 30 min at 37◦C, then incubated with an excess of α2-macroglobulin (500 µg/ml) for 30 min at 37◦C, and subsequently subjected to zymography. The dark protein band migrating on
top of the gel represents α2-macroglobulin (α2M), which binds and inhibits only active endopeptidases.
activated species, were detected by anti-(proMMP-9-prodomain)
antibodies (Figure 9A).
Western blot analysis using the MMP-9 propeptide-directed
antibodies was then applied to investigate whether the 82 kDa
proMMP-9 was also present in other cell types. We first examined
HL-60 and NB4 cells, which originate from patients with
acute myeloid leukaemia. The immunoblotting procedure clearly
showed prominent amounts of the 82 kDa proMMP-9 and a weak
band of 94 kDa proMMP-9 in extracts from PMA-stimulated HL-
60 and NB4 cells, consistent with the observations in THP-1
cells (Figure 9B). MMP-3 treatment of HL-60 and NB4 cell
lysates also generated the 35 kDa activated MMP-9 species
(results not shown), proving the presence of 82 kDa proMMP-9
in these cells. Western blot analysis of extracts from PMA-treated
ex vivo leukaemic cells isolated from the peripheral blood of three
patients with acute myeloid leukemia clearly displayed production
of the 82 kDa proMMP-9 in these cells (Figure 9B). In contrast,
proMMP-9 forms were absent from the lysates obtained from
PMA-stimulated mononuclear cells and neutrophil granulocytes
from peripheral blood of healthy donors (Figure 9B).
DISCUSSION
Cell surface-associated proteinases concentrate proteolytic events
at the sites of cell–matrix contact and mediate responses very
rapidly in contrast to secreted enzymes, which diffuse into the
pericellular space after their release [51]. Previous studies have
demonstrated localization of MMP-9 on the plasma membrane
of various tumour cells [6,24,26,31,33–36]. So far, it has been
assumed that surface-bound MMP-9 represents secreted enzyme
molecules that re-associate with the plasma membrane. In the
present study, we provide evidence for the existence of an
unique variant of MMP-9 zymogen with a molecular mass of
82 kDa that is not detectable in the culture medium, but is
present as the prominent proMMP-9 on the surface of leukaemic
cells. Moreover, this membrane associated proMMP-9 variant
differs from the secreted zymogen form in several structural and
functional aspects: it is truncated by nine amino acids at its N-
terminus, it lacks O-linked glycosylation and it exhibits a distinct
activation process which produces an unusually small active
MMP-9 species with less susceptibility to TIMP-1 inhibition.
Previous studies in immortalized MCF10A breast epithelial
cells demonstrated that secreted proMMP-9 was localized at the
plasma membrane together with an 85 kDa species of MMP-9,
which was not released from the cells even upon its stimulation
with PMA [26]. Thus, the latter form of MMP-9 appears to have
similar trafficking properties to the 82 kDa proMMP-9 described
in our THP-1 cell system. This 82 kDa species was absent in
medium, but readily detected in cell lysates and the plasma
membrane, suggesting that this enzyme is retained at the cell
c© The Authors Journal compilation c© 2007 Biochemical Society
Cell surface-associated 82 kDa proMMP-9 555
Figure 6 Autocatalytic activation of the 82 kDa proMMP-9
Purified 94 kDa proMMP-9 (94k) and 82 kDa proMMP-9 (82k) were diluted to a final
concentration of 0.5 nM in enzyme buffer and incubated at 37◦C with or without addition
of 1.5 nM TIMP-1. Aliquots were taken at different time intervals and analysed by zymography
(A) and Western blotting using a polyclonal anti-MMP-9 antibody (B).
surface by a unique interaction. Although the specific surface
receptors of 82 kDa proMMP-9 remain to be identified, proteins
known to attach secreted proMMP-9 to the plasma membrane,
such as CD44, collagen chains and various integrins [33–36],
might also act as binding partners for the 82 kDa zymogen. Direct
translocation of proMMP-9 from the intracellular pool to the cell
surface of activated neutrophils has been demonstrated to involve
complex formation with β2 integrins [28]. However, the mech-
anisms of trafficking and cell surface attachment for the 82 kDa
proMMP-9 variant remain to be determined.
Because MMP-9 bound to certain tumour cells has an apparent
molecular mass of approx. 83 kDa, it was suggested to represent
an activated species of secreted proMMP-9 [6,34]. Similarly, an
82 kDa gelatinase detected in lysates of PMA-treated endothelial
cells was claimed to represent the active form of MMP-9 [52].
However, a biochemical characterization of this cell-associated
low molecular mass MMP-9 was not reported. To elucidate the
molecular properties of the THP-1 cell-associated MMP-9, we
purified the 82 kDa species from the cell lysates and compared
it with the 94 kDa proMMP-9 released into the culture medium.
The results of the present study showed that the 82 kDa form
is a proMMP-9, but that the N-terminus is truncated by nine
amino acids. Previously it has been reported that proMMP-9
isolated from culture supernatants of peripheral blood monocytes,
Figure 7 Degradation of natural substrates
Collagen type IV (native or denatured; 400 µg/ml), collagen type I (denatured; 300 µg/ml) and
fibronectin (FN; 100 µg/ml) were incubated with or without equimolar amounts of auto-activated
82 kDa proMMP-9 (82k) and APMA-activated 94 kDa proMMP-9 (94k) for 48 h at 32◦C. The
reaction mixtures were then analysed for degradation products (DP) by SDS/PAGE and silver
staining of the proteins. α1(I), collagen type I chain α1(I); α2(I), collagen type I chain α2(I);
α1(IV), collagen type VI chain α1(IV); α2(IV), collagen type VI chain α2(IV).
neutrophil granulocytes and HL-60 leukaemic cells is also
shortened by eight to nine amino acids at its N-terminus [9,10,41].
This indicates that N-terminal processing may occur in both
surface-bound and secreted proMMP-9 forms, but the underlying
procedure is unclear. It can be speculated that intracellular
or membrane-associated proteinases might be involved in the
cleavage of the N-terminal peptide from 82 kDa proMMP-9, such
as pro-protein convertases, which post-translationally process
precursor proteins during the secretory pathway.
In addition to the lack of the nine N-terminal amino acids,
other structural modifications had to be assumed for the novel
82 kDa proMMP-9 to explain its reduced molecular mass.
Therefore we searched for alternatively spliced MMP-9 mRNAs,
but they were not detected in THP-1 cells (results not shown).
Deglycosylation studies, however, revealed that the surface-
bound 82 kDa proMMP-9 variant lacks O-linked carbohydrates,
which amount to a molecular mass of approx. 9 kDa in the
94 kDa proMMP-9. This finding is consistent with previous data
reporting that an epithelial cell membrane associated 85 kDa
variant of MMP-9 is not fully glycosylated [26]. Our results
on secreted proMMP-9 are in accordance with those of a
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Figure 8 Inhibition studies
Activated 82 kDa proMMP-9 and 94 kDa proMMP-9 (1 nM) were assayed with increasing
concentrations of the physiological MMP-9 inhibitor TIMP-1 (A) and the synthetic MMP-
inhibitor GM6001 (B). Residual enzyme activity was quantified using fluorescence-labelled
gelatin as a substrate and expressed in percentage of activity without inhibitor. Results are given
as means of duplicate experiments representative for three independent determinations.
detailed glycosylation analysis performed on proMMP-9 released
from neutrophil granulocytes, demonstrating that N-linked
carbohydrates of approx. 5 kDa and O-linked carbohydrates
of approx. 10 kDa are attached to the 76 kDa zymogen core
protein [53,54]. The biological significance of oligosaccharides
for proMMP-9 function is far from clear, but they are considered to
influence the backbone conformation of the enzyme, its stability
and its interaction with other molecules. Recent studies using
recombinant variants of proMMP-9 indicate that the abundant
O-linked glycans present in this enzyme are important for its
interaction with TIMP-1, but dispensable for catalytic activity
[55]. Likewise, O-glycans present in membrane type 1 MMP
are essential for binding to TIMP-2, but are not required
for its collagenolytic activity [56]. Additionally, aberrant O-
glycosylation found in tumour cell-derived proMMP-9 compared
with that from neutrophil granulocytes was shown to contribute
to impaired interaction with galectin-3 [57]. We hypothesize that
N-terminal processing of the 82 kDa proMMP-9 alters its protein
Figure 9 Specific detection of 82 kDa proMMP-9 in leukaemic and non-
leukaemic cells
(A) The zymogen forms (Pro) and activated species (Act.) of the 94 kDa proMMP-9 (94k) and the
82 kDa proMMP-9 (82k) were analysed by zymography. Aliquots were subjected to SDS/PAGE
under reducing condition, blotted and incubated with monoclonal antibodies directed against
the propeptide of proMMP-9 to allow specific detection of the 82 kDa proMMP-9 in distinction
to 82 kDa active MMP-9. (B) Cells were incubated in serum-free medium (1 × 106 cells/ml)
for 24 h in the presence of 50 ng/ml PMA. Proteins were extracted and 10 ng were subjected to
Western blotting analysis using an anti-(proMMP-9 prodomain) antibody. Results are shown for
the leukaemic cell lines THP-1, HL-60 and NB4, for mononuclear cells (MNC) and neutrophil
granulocytes (PMNC) from peripheral blood of healthy persons, and for leukaemic blast cells
from peripheral blood of patients with acute myeloid leukemia (Pat.#1-3).
structure in the endoplasmic reticulum and Golgi, which results
in the failure of O-glycosylation. Consequently, the lack of O-
glycans may favour surface binding and cause changes in its
interaction with substrates, inhibition by TIMPs and accessibility
to (auto-)proteolytic cleavage.
MMP-3 is an effective proteolytic activator for secreted
proMMP-9 [23,25,48,49] generating the active 82 kDa species.
In the present study, we could demonstrate that it converts the
surface-associated 82 kDa proMMP-9 into an unusually small and
so far undescribed 35 kDa active form. This species was found in
cell lysates and purified plasma membranes, but was absent in the
culture supernatants. This failure may be due to a strong binding
to the cell surface or caused by dilution and limited stability in the
medium. The 35 kDa MMP-9 has a substrate spectrum similar
to the well-known 82 kDa MMP-9, but preferentially cleaves
denatured collagens, suggesting a biological role differing from
that of secreted MMP-9. Moreover, autocatalytic conversion into
its active species occurred in the surface-bound 82 kDa proMMP-
9, but not in the secreted 94 kDa zymogen. This auto-activation
may be promoted by the lack of a nonapeptide at the N-terminus
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of the 82 kDa proMMP-9, which may disrupt the cysteine–
Zn2+ interaction (‘cysteine switch’) more readily. Although the
autoproteolytic activation of the 82 kDa proMMP-9 occurred at
a slower rate compared with the MMP-3 catalysed reaction, both
conditions led to the appearance of a major 35 kDa active species
and a minor 25 kDa form detectable in zymograms, indicating
that similar processing mechanisms may apply for autocatalytic
and MMP-3-mediated activation. TIMP-1 is known to build a
tight complex with the secreted 94 kDa proMMP-9 by binding
with its N-terminus to the catalytic site and with its C-terminus
to the haemopexin domain of proMMP-9, thereby controlling
its activation and activity [1,4,21,23,41,48]. Unexpectedly, co-
incubation of the 82 kDa proMMP-9 with an excess of TIMP-1
could not prevent or slow down the auto-activation, suggesting
limited reaction between the proenzyme variant and TIMP-1. This
may be explained by the lack of O-glycans in 82 kDa proMMP-9,
which were shown to be essential for optimal binding of
proMMP-9 to TIMP-1 [55].
To gain further insight into the structure/function relationship
of the 82 kDa proMMP-9, we performed comparative inhibition
studies. The activated 94 kDa proMMP-9 was efficiently
blocked by equimolar concentrations of TIMP-1, consistent
with the results of previous studies on secreted proMMP-9
[58]. In contrast, the 82 kDa proMMP-9 in its activated form
required approx. 80-fold higher amounts of TIMP-1 to abrogate
gelatinolytic activity. It seems obvious that this dramatically
reduced inhibition is related to the extensive truncations
characterizing active 35-kDa MMP-9. In fact, antibodies directed
against a C-terminal peptide of MMP-9 recognized 82 kDa
proMMP-9, but not its activated 35 kDa form (results not shown),
indicating C-terminal truncation in the latter. The C-terminus of
MMP-9 contains the haemopexin-like domain, which represents
the high-affinity binding site for TIMP-1 [55,58]. Therefore it
is reasonable that extensive C-terminal processing of the 82 kDa
proMMP-9 during activation reduces its susceptibility to TIMP-1
inhibition and thereby increases its bioavailability. Presumably,
the remaining 35 kDa mini MMP-9 essentially consists of the
catalytic domain of MMP-9. This area contains the fibronectin-
type II repeats, which are important for gelatin binding, and
includes the zinc-binding sequence that is required for proteolytic
activity [1,4]. GM6001, a small synthetic metalloproteinase
inhibitor that binds directly to the enzyme’s active site [59],
blocked the active 35 kDa and 82 kDa MMP-9 species with a
similar efficiency. This indicates the suitability of low molecular
mass inhibitors in targeting both surface-associated and secreted
MMP-9 activity, e.g. in the treatment of cancer.
The results of the present study indicate that THP-1 leukaemic
cells endogenously produce a unique proMMP-9 variant exposed
on the cell surface with reduced susceptibility to inhibition
by TIMP-1. Adopting an immunological method specifically
detecting this novel 82 kDa proMMP-9, we found the enzyme
to be expressed in different leukaemic cell lines, but not in normal
white blood cells. Its detection in patient-derived leukaemic blast
cells indicates that the 82 kDa proMMP-9 also occurs in vivo,
supporting the importance of this enzyme species. Physiological
stimuli such as cytokines, chemokines or extracellular matrix
components may influence its synthesis and exposition on the
plasma membrane. Therefore overexpression of the TIMP-1-
insensitive MMP-9 variant on the surface of malignantly trans-
formed cells may increase pericellular proteolysis and thereby
promote cancer progression in vivo.
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